drugset / Trial / NCT04689425

Umbilical Cord Blood Mononuclear Cell Gel in the Treatment of Refractory Diabetic Foot Ulcer

NCT04689425

Phase 3 Unknown 40 enrolled Peking University Third Hospital
RandomizedParallel-groupTriple-blindTreatment

Summary

Umbilical cord blood mononuclear cells (MNC) may improve the wound repair ability. This study aims to investigate the role of MNC in refractory diabetic foot ulcer by comparing the combination of PRP and MNC with PRP alone.

Timeline

Start
2021-03-30
Primary completion
2023-12-31
Completion
2024-12-31

Drugs

EvaluationDrugModalityDoseRoute
Subject Umbilical cord blood mononuclear cells Cell therapy Topical
Background Platelet Rich Plasma Other / unclassified Topical

Indications